
FDA Approves Entrectinib for NTRK Fusion-Positive Solid Tumors and Rare Lung Cancer
FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated. The FDA also gave approval to entrectinib for the treatment of adults with metastatic non–small cell lung cancer whose tumors are ROS1 positive.
FDA has granted accelerated approval to Genentech’s entrectinib, sold as Rozlytrek, for the treatment of adult and adolescent patients with solid tumors with that have the neurotrophic tyrosine receptor kinase (NTRK) gene fusion and for whom there are no effective treatments.
The approval of the tissue agnostic therapy represents a new paradigm in cancer treatment where cancers are treated based on a common biomarker seen across different tumors rather than based on the location in the body where the tumor originated. Last year, the
“We are in an exciting era of innovation in cancer treatment as we continue to see development in tissue agnostic therapies, which have the potential to transform cancer treatment,” FDA Acting Commissioner Ned Sharpless, MD, said
Four clinical trials brought promising data for entrictinib and its ability to shrink NTRK fusion-positive tumors. Across the trials, there was an overall response rate (ORR) of 57%, with 7.4% of patients achieving a complete response (CR). There were 31 patients who had tumor shrinkage, 61% of which had responses that lasted 9 months or longer. The most common cancer locations were in the lung, salivary gland, breast, thyroid, and colon/rectum.
The FDA also gave approval to entrectinib for the treatment of adults with metastatic non—small cell lung cancer whose tumors are ROS1 positive.
“Rozlytrek’s FDA approval for two rare types of cancer is an important advance for patients, combining a targeted medicine and genomic testing to bring this new treatment option to patients who are waiting,” Sandra Horning, MD, chief medical officer and head of Global Product Development, Genentech, said
Common side effects of the treatment include fatigue, constipation, dysgeusia, edema, dizziness, cognitive impairment, weight gain, cough fever, and vision disorders. The most serious side effects include congestive heart failure, central nervous system effects, skeletal fractures, liver damage, and abnormal heart rhythm.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.